The most notable preclinical study of GM-CSF was an in-vivo screen by Dranoff and colleagues: tumor cell lines carrying various immunostimulatory agents were used to immunize mice, and vaccination with the GM-CSF expressing cells provided the greatest protection against later engraftment when mice were challenged with the parental tumor cell lines [99]. Here, CSF2 is linked to neoplasm.